Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022
May 02, 2022 16:30 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting
May 01, 2022 14:15 ET
|
Adverum Biotechnologies, Inc.
- Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean annualized anti-VEGF injections ranged from 81%...
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022
April 19, 2022 18:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA
April 06, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
March 29, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of Directors
March 17, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference
February 28, 2022 08:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer
February 07, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
- Dr. Beckman, a board-certified ophthalmologist, brings 30 years of experience in ophthalmology, drug development and retinal diseases including wet age-related macular degeneration - REDWOOD CITY,...
Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer
January 06, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...